The Egyptian Heart Journal (Jan 2021)

Effect of discontinuation of ticagrelor and switching-over to other P2Y12 agents in patients with acute coronary syndrome: a single-center real-world experience from India

  • Nagendra Boopathy Senguttuvan,
  • Ramesh Sankaran,
  • Yashasvi Rajeev,
  • Devi Thaiyal,
  • Angel Mathew,
  • K. Dharsini,
  • Divya Marcelene,
  • Maria Jusler Kalsingh,
  • Sujit Kumar Sahu,
  • Aravind Sampath,
  • K. J. Prem Kumar,
  • Harikrishnan Parthasarathy,
  • Amal Louis,
  • Anand Gnanaraj,
  • K. N. Reddy,
  • K. A. Abraham

DOI
https://doi.org/10.1186/s43044-020-00128-3
Journal volume & issue
Vol. 73, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Dual antiplatelet therapy is the current standard of care after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). We intended to study the pattern of use of ticagrelor in patients with acute coronary syndrome undergoing PCI and the effect of switching over to other P2Y12 receptor inhibition on clinical outcomes. Results All patients aged > 18 years who had been admitted with acute coronary syndrome and had been provided ticagrelor as the second antiplatelet agent were included as study participants. The primary outcome of the study was the composite outcome of death, recurrent myocardial infarctions, re-intervention, and major bleeding. We studied 321 patients (54 female patients, 16.82%). The mean age of the patients was 56.65 ± 11.01 years. Ticagrelor was stopped in 76.7% on follow-up. It was stopped in 6.3%, 13.5%, 13.1%, 21.9%, and 45.1% of patients during the first month but after discharge, between first and third months, between 3 and 6 months, between 6 and 12 months, and after 12 months, respectively. In the majority of patients, ticagrelor was replaced by clopidogrel (97.9%). It was stopped according to the physician’s discretion in 79.3% of patients, whereas it was the cost of the drug that made the patient to get swapped to another agent in 18.6%. No difference in the primary composite outcome was observed between the groups where ticagrelor was continued post 12 months and ticagrelor was continued and ticagrelor was switched-over to another agent. Similarly, no difference in death, recurrent myocardial infarctions, re-interventions, or major bleeding manifestations was observed between the two groups. Conclusion In patients with acute coronary syndrome who undergo PCI, we observed that early discontinuation of ticagrelor and switching over to other P2Y12 inhibitors after discharge did not affect clinical outcomes.

Keywords